Idenix Pharmaceuticals’s Equal Weight Rating Reaffirmed at Barclays (IDIX)
Idenix Pharmaceuticals (NASDAQ:IDIX)‘s stock had its “equal weight” rating reiterated by investment analysts at Barclays in a note issued to investors on Friday, American Banking News reports. They currently have a $5.00 target price on the stock, up from their previous target price of $4.00. Barclays’ target price indicates a potential downside of 29.08% from the stock’s previous close.
Shares of Idenix Pharmaceuticals (NASDAQ:IDIX) opened at 7.05 on Friday. Idenix Pharmaceuticals has a 52-week low of $2.93 and a 52-week high of $7.48. The stock has a 50-day moving average of $5.55 and a 200-day moving average of $4.55. The company’s market cap is $944.7 million.
Idenix Pharmaceuticals (NASDAQ:IDIX) last announced its earnings results on Wednesday, October 30th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.04. On average, analysts predict that Idenix Pharmaceuticals will post $-0.92 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at UBS AG upgraded shares of Idenix Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note to investors on Monday. They now have a $11.00 price target on the stock, up previously from $4.00. Analysts at Credit Suisse upgraded shares of Idenix Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note to investors on Wednesday, October 16th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. Idenix Pharmaceuticals has an average rating of “Hold” and a consensus price target of $5.08.
Idenix Pharmaceuticals, Inc (NASDAQ:IDIX) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.